Will Outlook Therapeutics Inc (NASDAQ: OTLK) In 2023 Be Worth Your Money?

In the last trading session, 2.01 million Outlook Therapeutics Inc (NASDAQ:OTLK) shares changed hands as the company’s beta touched 0.40. With the company’s per share price at $0.46 changed hands at $0.02 or 5.43% during last session, the market valuation stood at $119.74M. OTLK’s last price was a discount, traded about -341.3% off its 52-week high of $2.03. The share price had its 52-week low at $0.20, which suggests the last value was 56.52% up since then. When we look at Outlook Therapeutics Inc’s average trading volume, we note the 10-day average is 3.4 million shares, with the 3-month average coming to 11.30 million.

Outlook Therapeutics Inc (NASDAQ:OTLK) trade information

Instantly OTLK was in green as seen at the end of in last trading. With action 15.02%, the performance over the past five days has been green. The jump to weekly highs of 0.4693 on Friday, 11/17/23 added 5.43% to the stock’s daily price. The company’s shares are showing year-to-date downside of -57.40%, with the 5-day performance at 15.02% in the green. However, in the 30-day time frame, Outlook Therapeutics Inc (NASDAQ:OTLK) is -30.29% down. Looking at the short shares, we see there were 32.03 million shares sold at short interest cover period of 2.47 days.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of $2.18 million. 6 analysts are of the opinion that Outlook Therapeutics Inc’s revenue for the quarter ending Dec 2023 will be $2.7 million.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 53.55%. The 2023 estimates are for Outlook Therapeutics Inc earnings to increase by 21.15%.

OTLK Dividends

Outlook Therapeutics Inc is expected to release its next quarterly earnings report between December 27 and January 01.

Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 60.70% of Outlook Therapeutics Inc shares while 10.64% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 27.06%. There are 10.64% institutions holding the Outlook Therapeutics Inc stock share, with Blackrock Inc. the top institutional holder. As of Sep 29, 2023, the company held 3.61% of the shares, roughly 9.39 million OTLK shares worth $4.32 million.

Vanguard Group Inc holds the second largest percentage of outstanding shares, with 2.41% or 6.28 million shares worth $2.89 million as of Sep 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.61 million shares estimated at $1.66 million under it, the former controlled 1.39% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.38% of the shares, roughly 3.58 million shares worth around $1.65 million.

On Key

Related Posts